137 related articles for article (PubMed ID: 9694157)
1. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery.
O'Neal WK; Zhou H; Morral N; Aguilar-Cordova E; Pestaner J; Langston C; Mull B; Wang Y; Beaudet AL; Lee B
Hum Gene Ther; 1998 Jul; 9(11):1587-98. PubMed ID: 9694157
[TBL] [Abstract][Full Text] [Related]
2. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.
Morral N; O'Neal W; Zhou H; Langston C; Beaudet A
Hum Gene Ther; 1997 Jul; 8(10):1275-86. PubMed ID: 9215744
[TBL] [Abstract][Full Text] [Related]
3. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors.
Pastore L; Morral N; Zhou H; Garcia R; Parks RJ; Kochanek S; Graham FL; Lee B; Beaudet AL
Hum Gene Ther; 1999 Jul; 10(11):1773-81. PubMed ID: 10446917
[TBL] [Abstract][Full Text] [Related]
4. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector.
O'Neal WK; Zhou H; Morral N; Langston C; Parks RJ; Graham FL; Kochanek S; Beaudet AL
Mol Med; 2000 Mar; 6(3):179-95. PubMed ID: 10965494
[TBL] [Abstract][Full Text] [Related]
5. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
Van Linthout S; Lusky M; Collen D; De Geest B
Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
[TBL] [Abstract][Full Text] [Related]
6. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity.
Morral N; Parks RJ; Zhou H; Langston C; Schiedner G; Quinones J; Graham FL; Kochanek S; Beaudet AL
Hum Gene Ther; 1998 Dec; 9(18):2709-16. PubMed ID: 9874269
[TBL] [Abstract][Full Text] [Related]
7. Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice.
Schowalter DB; Himeda CL; Winther BL; Wilson CB; Kay MA
J Virol; 1999 Jun; 73(6):4755-66. PubMed ID: 10233936
[TBL] [Abstract][Full Text] [Related]
8. A Cre-expressing cell line and an E1/E2a double-deleted virus for preparation of helper-dependent adenovirus vector.
Zhou H; Zhao T; Pastore L; Nageh M; Zheng W; Rao XM; Beaudet AL
Mol Ther; 2001 Apr; 3(4):613-22. PubMed ID: 11319924
[TBL] [Abstract][Full Text] [Related]
9. Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses.
Raper SE; Haskal ZJ; Ye X; Pugh C; Furth EE; Gao GP; Wilson JM
Hum Gene Ther; 1998 Mar; 9(5):671-9. PubMed ID: 9551615
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
11. Constitutive expression of murine CTLA4Ig from a recombinant adenovirus vector results in prolonged transgene expression.
Schowalter DB; Meuse L; Wilson CB; Linsley PS; Kay MA
Gene Ther; 1997 Aug; 4(8):853-60. PubMed ID: 9338015
[TBL] [Abstract][Full Text] [Related]
12. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
13. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity.
Schiedner G; Morral N; Parks RJ; Wu Y; Koopmans SC; Langston C; Graham FL; Beaudet AL; Kochanek S
Nat Genet; 1998 Feb; 18(2):180-3. PubMed ID: 9462752
[TBL] [Abstract][Full Text] [Related]
14. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors.
Lieber A; He CY; Meuse L; Schowalter D; Kirillova I; Winther B; Kay MA
J Virol; 1997 Nov; 71(11):8798-807. PubMed ID: 9343240
[TBL] [Abstract][Full Text] [Related]
15. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons.
Morral N; O'Neal W; Rice K; Leland M; Kaplan J; Piedra PA; Zhou H; Parks RJ; Velji R; Aguilar-Córdova E; Wadsworth S; Graham FL; Kochanek S; Carey KD; Beaudet AL
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12816-21. PubMed ID: 10536005
[TBL] [Abstract][Full Text] [Related]
16. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors.
Everett RS; Hodges BL; Ding EY; Xu F; Serra D; Amalfitano A
Hum Gene Ther; 2003 Dec; 14(18):1715-26. PubMed ID: 14670123
[TBL] [Abstract][Full Text] [Related]
17. Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs.
Fang B; Wang H; Gordon G; Bellinger DA; Read MS; Brinkhous KM; Woo SL; Eisensmith RC
Gene Ther; 1996 Mar; 3(3):217-22. PubMed ID: 8646552
[TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
19. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors.
Song S; Embury J; Laipis PJ; Berns KI; Crawford JM; Flotte TR
Gene Ther; 2001 Sep; 8(17):1299-306. PubMed ID: 11571566
[TBL] [Abstract][Full Text] [Related]
20. Germline incorporation of a replication-defective adenoviral vector in mice does not alter immune responses to adenoviral vectors.
Camargo FD; Huey-Louie DA; Finn AV; Sassani AB; Cozen AE; Moriwaki H; Schneider DB; Agah R; Dichek DA
Mol Ther; 2000 Nov; 2(5):496-504. PubMed ID: 11082323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
